MBX Biosciences, Inc.

We’d like to thank everyone who joined us for our presentation, as well as express our gratitude to the HypoPARAthyroidism Association for hosting a fantastic event earlier this month!    It is especially meaningful to see such strong engagement from the #hypoparathyroidism patient community – the conversations and questions throughout the event reflected a shared optimism about the future of the HP treatment landscape.      #hypopara2025 

Members of our management team are attending the 2025 International HypoPARAthyroidism Conference, hosted by the HypoPARAthyroidism Association, this October 3-5.     Andreas G. Moraitis, MD, our Sr. Vice President of Clinical Development, will present the recently announced 12-week and 6-month topline results from the Phase 2 clinical trial evaluating our potential once-weekly parathyroid hormone (PTH) replacement therapy.     We look forward to engaging with members of the HP community in person in Grapevine, TX, and invite those who cannot physically attend to register virtually: https://lnkd.in/exPSnS6E

Tomorrow, our CEO, Kent Hawryluk, and CMO, Salomon (Sam) Azoulay, MD, will participate in a fireside chat at the Stifel 2025 Virtual Cardiometabolic Forum.    Listen in, from 10:00-10:25 a.m. ET: https://lnkd.in/epJeWxns Stifel Financial Corp.

#NEWS: Today, we shared that our investigational once-weekly parathyroid hormone (PTH) replacement therapy for #hypoparathyroidism achieved the primary endpoint in the 12-week Phase 2 trial with a 63% responder rate which increased to 79% at 6 months in the open-label extension.     This is a significant milestone, which reflects the commitment of our dedicated clinical trial investigators, the incredible MBX team, and above all, the patients – whose support and engagement helped carry this clinical trial forward.    We look forward to initiating our Phase 3 trial next year.     MBX management will host a webcast at 8 am ET to discuss the Phase 2 results and next steps. Read the press release here: https://lnkd.in/e9WD8CdW

We announced today that the first participant has been dosed in the Phase 1 trial of our Precision Endocrine Peptide (PEP) glucagon-like peptide-1 (GLP-1)/ glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug for the treatment of #obesity.    Thank you to our talented team, whose dedication to improving the lives of patients affected by obesity brought this milestone to fruition.    Read the press release here: https://lnkd.in/eJmz6umG

Today, we shared our Q2 2025 financial results. View our corporate highlights and upcoming milestones in the press release: https://lnkd.in/e8xtNG9X

Today, our CEO & Co-Founder, Kent Hawryluk and CMO, Salomon (Sam) Azoulay, M.D., will participate in a fireside chat at the private virtual UBS Biotech Management Live Call Series.

We’re proud to share that our Chief Executive Officer and co-founder, Kent Hawryluk, and co-founder, Richard DiMarchi, Ph.D., have been named to the 2025 Indiana 250: a list of the state’s most influential and impactful business and community leaders, for the second year in a row.     IBJ Media, Indianapolis Business Journal, and Inside INdiana Business recognize leaders in Indiana, such as Kent and Richard, for their vision and contributions to leading therapeutic innovation to improve lives throughout our patient communities and beyond. View the full list here: indiana250.com #Indiana250

This week, Richard DiMarchi, Ph.D., Indiana University Bloomington professor, MBX co-founder, and innovator in the field of peptides, will present on the discovery process for our novel investigational parathyroid hormone replacement therapy at the 2nd Annual Hypoparathyroidism Summit.     Learn more about the summit: https://lnkd.in/eRJTGsSP   

At MBX Biosciences, we have a clear mission to help people with #endocrine and #metabolic disorders live fuller and healthier lives. Every member of our growing team plays a role in turning that mission into reality through scientific innovation, cross-functional teamwork, and an unwavering commitment to meeting unmet patient needs. If you’re inspired by purpose-driven work and want to be part of a team that’s advancing therapies with real impact, explore our open positions: mbxbio.com/careers